Clinical Trials Logo
  1. Home
  2. Drug-drug Interaction
  3. NCT06119958
  4. Details
NCT06119958 Clinical Trial

Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

Drug Drug Interaction Clinical Trial

Official title:
A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Crossover Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of DWC202313 and DWC202314 in Healthy Adult Volunteers

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06119958
Other study ID # DWJ1622101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 27, 2023
Est. completion date December 2023

Study information
Verified date October 2023
Source Daewoong Pharmaceutical Co. LTD.
Contact Seung-Hyun Kang, MD, Ph D
Phone 070-4665-9490
Email juspa@newyjh.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.

Recruitment information / eligibility
Status Recruiting
Enrollment 32
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 45 Years
Eligibility Inclusion Criteria: - over 19 year old Exclusion Criteria: - Galactose intolerance - Lapp lactase deficiency

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• DWC202313
Experimental Drug 1
• DWC202314
Experimental Drug 2

Locations
Country Name City State
Korea, Republic of H Plus YANGJI Hospital Seoul

Sponsors (1)
Lead Sponsor Collaborator
Daewoong Pharmaceutical Co. LTD.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Cmax,ss of DWC202313 and DWC202314 Up to 14 days
Primary AUCt,ss of DWC202313 and DWC202314 Up to 14 days
Secondary Tmax,ss of DWC202313 and DWC202314 Up to 14 days
Secondary Cmin,ss of DWC202313 and DWC202314 Up to 14 days
Secondary t1/2 of DWC202313 and DWC202314 Up to 14 days
Secondary CLss/F of DWC202313 and DWC202314 Up to 14 days
Secondary Vdss/F of DWC202313 and DWC202314 Up to 14 days
Secondary PTF of DWC202313 and DWC202314 Up to 14 days
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Completed NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects Phase 1
Active, not recruiting NCT05812404 - Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT04542252 - Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT03103568 - A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Phase 1
Completed NCT05860114 - Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1
Completed NCT03909529 - Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) Phase 1